 |
 |
Quoting Nic Marais <[log in to unmask]>: > Isn't that what Eldepryl was also supposed to do? > > I feel like a Pawn.... > > Nic 56,14 > > On Mon, Jun 16, 2008 at 8:21 PM, rayilynlee <[log in to unmask]> wrote: > > > Teva, Lundbeck say Azilect slows Parkinson's > > > > Reuters - 41 minutes ago > > TEL AVIV/STOCKHOLM, June 16 - Teva Pharmaceutical Industries Ltd revealed > > positive results on Monday for its Azilect Parkinson's treatment, boosting > > its shares and those of Danish partner Lundbeck . > > Tel Aviv-traded shares in Teva jumped 3.2 percent while Lundbeck was up > 3.7 > > percent at 1336 GMT. > > Teva, the world's biggest maker of generic drugs, said it intends to > submit > > these results to the regulatory authorities in the United States and > Europe. > > It said the 1 mg tablets of its Azilect drug slowed the progression of > > Parkinson's disease in a Phase III trial. It promotes the drug with > Lundbeck > > in the three major European markets: Britain, Germany and France. > > Teva and Lundbeck said 1 mg tablets of Azilect met all three primary end > > points in the trial, as well as the secondary and additional end points, > all > > with statistical significance. > > The study also confirmed the safety and tolerability of Azilect and based > > on these results, Azilect could become the first Parkinson's disease > > treatment to receive an indication for slowing the progress of the > disease, > > the companies said. > > "These positive results could dramatically increase the market potential > > for Azilect, allowing Azilect to join Copaxone as another major Teva drug > > for neurological disorders," Shlomo Yanai, president and chief executive > of > > Teva, said in a statement. > > Teva's Copaxone became the No. 1 global treatment for multiple sclerosis > in > > the first quarter. > > "Azilect, an innovative drug that was not very significant, becomes a drug > > with the potential to be a blockbuster," said Gal Reiter, an analyst at > > Israeli brokerage Clal Finance. > > SALES TO JUMP > > Global sales of Azilect rose 50 percent in the first quarter from a year > > earlier to $37.5 million. It sales were $120 million in 2007. > > "If in the past we estimated the potential sales of the drug at $300 > > million, now we estimate that the potential has at least doubled," Reiter > > said. > > "However, it will take time until Azilect's impact becomes substantial." > > The analyst noted that while Azilect's patent runs until 2012, this > > clinical trial could enable an extension until 2017. > > Bank Hapoalim analyst Gilad Sarig estimated Azilect's potential sales at > $1 > > billion. > > "It is expected to become the leading drug in the Parkinson's market > within > > a few years," he said in a research note, adding he is not changing his > > forecasts for the company until the timetable with the FDA becomes clear. > > The study protocol was based on the recommendations and guidance of the > > U.S. Food and Drug Administration. The 18-month study, the first of its > > kind, is one of the largest conducted in Parkinson's disease, involving > > 1,176 patients with early Parkinson's disease in 14 countries and 129 > > medical centres. > > Teva also said the 2 mg dose in the study met two of the three primary end > > points as well as the secondary end point. It was also found to be safe > and > > well tolerated. > > Rayilyn Brown > > Director AZNPF > > Arizona Chapter National Parkinson Foundation > > [log in to unmask] > > ---------------------------------------------------------------------- > > To sign-off Parkinsn send a message to: mailto: > > [log in to unmask] > > In the body of the message put: signoff parkinsn > > > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------- This mail sent through http://www.ukonline.net ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn